444170 Manumycin A, Streptomyces parvulus - CAS 52665-74-4 - Calbiochem

444170
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₃₁H₃₈N₂O₇ 52665-74-4

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      444170-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewAn antibiotic with antitumor properties. A cell-permeable potent and selective inhibitor of farnesyltransferase (FTase; IC50 = 5 µM) compared to geranylgeranyltransferase I (GGTase I; IC50 = 180 µM). Manumycin acts as a competitive inhibitor of FTase with respect to farnesylpyrophosphate (FPP; Ki = 1.2 µM), but acts as a noncompetitive inhibitor with respect to the Ras acceptor protein. Reported to inhibit the growth and invasive activity of pancreatic cancer cells.
          Catalogue Number444170
          Brand Family Calbiochem®
          References
          ReferencesKainuma, O., et al. 1997. Pancreas 15, 379.
          Nagase, T., et al. 1996. Int. J. Cancer 65, 620.
          Hara, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 3333.
          Hara, M., et al. 1993. Proc. Natl. Acad. Sci. USA 90, 2281.
          Tamanoi, R. 1993. Trends Biochem. Sci. 18, 349.
          Product Information
          CAS number52665-74-4
          ATP CompetitiveN
          FormYellow to brown solid
          Hill FormulaC₃₁H₃₈N₂O₇
          Chemical formulaC₃₁H₃₈N₂O₇
          ReversibleN
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetFarnesyltransferase (FTAse)
          Primary Target IC<sub>50</sub>5 µM against farnesyltransferase (FTase); 180 µM against geranylgeranyltransferase I (GGTase I)
          Purity≥96% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          444170

          References

          Reference overview
          Kainuma, O., et al. 1997. Pancreas 15, 379.
          Nagase, T., et al. 1996. Int. J. Cancer 65, 620.
          Hara, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 3333.
          Hara, M., et al. 1993. Proc. Natl. Acad. Sci. USA 90, 2281.
          Tamanoi, R. 1993. Trends Biochem. Sci. 18, 349.

          Citations

          Title
        • Karen E. Porter, et al. (2004) Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovascular Research 61, 745-755.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision19-May-2009 JSW
          DescriptionAn antibiotic with antitumor properties. A potent and selective inhibitor of farnesyltransferase (FTase, IC50 = 5 µM) compared to geranyl-geranyltransferase I (GGTase, IC50 = 180 µM). Manumycin acts as a competitive inhibitor of FTase with respect to farnesylpyrophosphate (FPP, Ki = 1.2 µM), but as a noncompetitive inhibitor with respect to the Ras acceptor protein. Reported to inhibit the growth and invasive activity of pancreatic cancer cells.
          FormYellow to brown solid
          CAS number52665-74-4
          Chemical formulaC₃₁H₃₈N₂O₇
          Structure formulaStructure formula
          Purity≥96% by HPLC
          SolubilityDMSO (10 mg/ml), Methanol or Chloroform
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C).
          Toxicity Standard Handling
          ReferencesKainuma, O., et al. 1997. Pancreas 15, 379.
          Nagase, T., et al. 1996. Int. J. Cancer 65, 620.
          Hara, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 3333.
          Hara, M., et al. 1993. Proc. Natl. Acad. Sci. USA 90, 2281.
          Tamanoi, R. 1993. Trends Biochem. Sci. 18, 349.
          Citation
        • Karen E. Porter, et al. (2004) Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovascular Research 61, 745-755.